









Markets
/
Stocks
/
nasdaq-ibio
/

iBio Inc

IBIO

2.420USD

+0.270+12.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

49.02MMarket Cap

LossP/E TTM



iBio Inc

2.420

+0.270+12.56%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of iBio Inc

Currency: USD Updated: 2026-02-06

Key Insights

iBio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.52.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

iBio Inc's Score

Industry at a Glance

Industry Ranking

95 / 392

Overall Ranking

222 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

iBio Inc Highlights

StrengthsRisks

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 400.00K.

Undervalued

The company’s latest PE is -1.73, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 13.36M shares, increasing 42.84% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 883.15K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.13.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

4.520

Target Price

+110.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of iBio Inc is 7.59, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.59

Change



Financials

9.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.09

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.48

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

iBio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of iBio Inc is 8.56, ranking 37 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.73, which is -316.28% below the recent high of 3.75 and -117356.32% above the recent low of -2035.75.

Score

Industry at a Glance

Previous score

8.56

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of iBio Inc is 8.80, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 6.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

4.520

Target Price

+110.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

iBio Inc

IBIO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of iBio Inc is 5.67, ranking 303 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.87 and the support level at 2.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.27

Change

0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.037

Neutral

RSI(14)

58.031

Neutral

STOCH(KDJ)(9,3,3)

61.764

Buy

ATR(14)

0.207

Low Volatility

CCI(14)

151.938

Buy

Williams %R

15.789

Overbought

TRIX(12,20)

0.304

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.262

Buy

MA10

2.222

Buy

MA20

2.309

Buy

MA50

1.996

Buy

MA100

1.532

Buy

MA200

1.167

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of iBio Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 55.93%, representing a quarter-over-quarter increase of 227.16%. The largest institutional shareholder is The Vanguard, holding a total of 883.15K shares, representing 3.70% of shares outstanding, with 153.68% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EcoR1 Capital, LLC

2.23M

SilverArc Capital Management, LLC

2.18M

Logos Global Management LP

2.00M

Frazier Life Sciences Management, L.P.

1.95M

Lynx1 Capital Advisors LLC

1.66M

+56.82%

The Vanguard Group, Inc.

Star Investors

274.07K

+90.51%

Ikarian Capital LLC

599.91K

-2.82%

Crutcher (Patrick J)

546.61K

-21.55%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of iBio Inc is 1.21, ranking 340 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. iBio Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.